Deep in talks with J&J, Acte­lion’s flag­ship drug cruis­es past a piv­otal tri­al fail­ure

Deep in­to ne­go­ti­a­tions with J&J over a prospec­tive buy­out, Acte­lion (SIX: ATLN) re­port­ed to­day that its up-and-com­ing flag­ship ther­a­py Op­sum­it flunked a piv­otal test for treat­ing pul­monary ar­te­r­i­al hy­per­ten­sion due to Eisen­menger Syn­drome. And while the tri­al fail­ure could put a crimp in Acte­lion’s — as well as J&J’s — plan to con­tin­ue to rapid­ly boost sales of Op­sum­it as Tr­a­cleer los­es ground to gener­ic com­pe­ti­tion, an­a­lysts seemed ready to write it off and move on.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.